Search
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis.
Prostaglandin E synthase 3
go.drugbank.com/bio_entities/BE0002480TargetHumansCytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) (PubMed:10922363). Molecular chaperone that localizes to genomic response elements in a hormone-depende...
Synonyms: Progesterone receptor complex p23Proteasome subunit alpha type-2
go.drugbank.com/bio_entities/BE0003911TargetHumansComponent of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)
Synonyms: Multicatalytic endopeptidase complex subunit C3Proteasome subunit beta type-7
go.drugbank.com/bio_entities/BE0003920TargetHumansWithin the 20S core complex, PSMB7 displays a trypsin-like activity … Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.
Synonyms: Multicatalytic endopeptidase complex chain ZAtacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … [L63797,L63928] The approval is conditional on a proven reduction of proteinuria in the Origin 3 trial, which is evaluating whether the atacicept slows long-term kidney function decline.
Mesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalAn anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022]. … Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigational[A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment. … It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis.
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].
Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalIt is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].